- Home
- GLPG vs WLY Comparison
GLPG vs WLY Comparison
Compare GLPG & WLY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GLPG
- WLY
- Stock Information
- Founded
- GLPG 1999
- WLY 1807
- Country
- GLPG Belgium
- WLY United States
- Employees
- GLPG N/A
- WLY N/A
- Industry
- GLPG Biotechnology: Pharmaceutical Preparations
- WLY Books
- Sector
- GLPG Health Care
- WLY Consumer Discretionary
- Exchange
- GLPG Nasdaq
- WLY Nasdaq
- Market Cap
- GLPG 2.1B
- WLY 2.1B
- IPO Year
- GLPG 2005
- WLY N/A
- Fundamental
- Price
- GLPG $31.44
- WLY $40.58
- Analyst Decision
- GLPG Sell
- WLY
- Analyst Count
- GLPG 4
- WLY 0
- Target Price
- GLPG $25.33
- WLY N/A
- AVG Volume (30 Days)
- GLPG 345.0K
- WLY 364.9K
- Earning Date
- GLPG 07-23-2025
- WLY 09-04-2025
- Dividend Yield
- GLPG N/A
- WLY 3.45%
- EPS Growth
- GLPG N/A
- WLY N/A
- EPS
- GLPG N/A
- WLY 1.53
- Revenue
- GLPG $323,674,692.00
- WLY $1,677,609,000.00
- Revenue This Year
- GLPG N/A
- WLY $1.45
- Revenue Next Year
- GLPG N/A
- WLY $2.70
- P/E Ratio
- GLPG N/A
- WLY $26.72
- Revenue Growth
- GLPG 5.43
- WLY N/A
- 52 Week Low
- GLPG $22.36
- WLY $36.50
- 52 Week High
- GLPG $33.86
- WLY $53.96
- Technical
- Relative Strength Index (RSI)
- GLPG 47.00
- WLY 55.14
- Support Level
- GLPG $31.39
- WLY $39.60
- Resistance Level
- GLPG $32.43
- WLY $41.37
- Average True Range (ATR)
- GLPG 0.77
- WLY 0.68
- MACD
- GLPG -0.22
- WLY 0.30
- Stochastic Oscillator
- GLPG 7.22
- WLY 78.12
About GLPG Galapagos NV
Galapagos NV is a fully integrated biotechnology company with operations in Europe and the United States, dedicated to developing medicines focusing on oncology and immunology. The group focuses on unmet medical needs, it synergizes compelling science, technology, and collaborative approaches to create a deep pipeline of medicines. Its clinical pipeline includes: GLPG5101, a CD19 CAR-T product candidate decentralized manufactured, currently in Phase 1/2 in rrNHL; GLPG5301, a BCMA CAR-T product candidate decentralized manufactured, currently in Phase 1 in rrMM; and GLPG3667, a TYK2 inhibitor currently in Phase 2 clinical trial in DM and SLE. It derives maximum revenue from the United States of America.
About WLY John Wiley & Sons Inc.
John Wiley & Sons Inc is one of the world's greatest publishers and a trusted leader in research and learning. Its industry-principal content, services, platforms, and knowledge networks are tailored to meet the evolving needs of its customers and partners, including researchers, students, instructors, professionals, institutions, and corporations. The company empowers knowledge-seekers to transform today's obstacles into tomorrow's brightest opportunities. For more than two centuries, the company has been delivering on its timeless mission to unlock human potential.